CytoFab

sterile, nonpyrogenic, affinity-purified and lyophilized preparation of ovine fab IgG fragments obtained from blood of healthy sheep immunized with recombinant human TNF-alpha

Networked: 2 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barochia, Amisha: 1 article (11/2011)
2.	Cui, Xizhong: 1 article (11/2011)
3.	Eichacker, Peter Q: 1 article (11/2011)
4.	Li, Yan: 1 article (11/2011)
5.	Natanson, Charles: 1 article (11/2011)
6.	Qiu, Ping: 1 article (11/2011)
7.	Bernard, Gordon R: 1 article (09/2006)
8.	Edens, Tonya R: 1 article (09/2006)
9.	Morris, Peter E: 1 article (09/2006)
10.	Paz, Harold L: 1 article (09/2006)

Related Diseases

1.	Sepsis (Septicemia) 09/01/2006 - "Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis." 11/01/2011 - "An overview of the biology of TNF and experimental data implicating TNF as a key mediator in sepsis pathogenesis; a review of the earlier clinical experience with anti-TNF therapies demonstrating that when examined across 12 trials, these agents had a highly consistent overall effect which although not reaching significance, was on the side of benefit; a review of data showing that sepsis-associated risk of death may influence the efficacy of anti-inflammatory agents like anti-TNF ones and a review of the rational and clinical experience to date with AZD9773 and its precursor, CytoFab. " 09/01/2006 - "CytoFab is well tolerated in patients with severe sepsis, effectively reducing serum and BAL TNF-alpha and serum IL-6 concentrations and increasing the number of ventilator-free and ICU-free days at day 28."
2.	Shock 09/01/2006 - "The number of shock-free days did not differ between CytoFab and placebo (10.7 vs. 9.4, respectively) (p = .270). " 09/01/2006 - "This trial was designed to evaluate the safety and effectiveness of polyclonal ovine anti-TNF fragment antigen binding (Fab) fragments (CytoFab) on plasma TNF-alpha, interleukin-6 (IL-6), and interleukin-8 (IL-8) concentrations and the number of shock-free and ventilator-free days in severely septic patients. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Anti-Inflammatory Agents (Anti-Inflammatories)
3.	AZD9773
4.	Interleukin-8 (Interleukin 8)
5.	Interleukin-6 (Interleukin 6)
6.	Immunoglobulin Fab Fragments
7.	Antigens

Related Therapies and Procedures

1.	Therapeutics
2.	Mechanical Ventilators (Ventilator)